Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist" is generating significant coverage in the Business category, with 6 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, Trefis, Seeking Alpha and Investing.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 19d ago.
Quick answers
Why is "Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist" trending?
Because 5 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (18)
- Iovance Sinks Another 11% as Baird Cuts Target to $9 After Lung Cancer Data TIKR.com · 18d ago
- TIL Therapy Plus Pembrolizumab for Advanced Melanoma The ASCO Post · 18d ago
- Iovance Eyeing Biomarker-Informed Lung Cancer as Next Amtagvi Indication GenomeWeb · 18d ago
- Is 50% Crash Risk For Iovance Stock Real? Trefis · 19d ago
- Iovance stock falls after lung cancer trial data disappoints Investing.com · 19d ago
- Iovance Biotherapeutics (IOVA) Posts 59.1% Response In Lifileucel Lung Cancer Study Yahoo Finance · 19d ago
- Iovance Sinks 31% as Lung Cancer TIL Data Comes In “Consistent With Previously Reported Results” TIKR.com · 19d ago
- Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy GlobeNewswire · 19d ago
- Iovance plummets on new phase 2 Amtagvi data for non-small-cell lung cancer Seeking Alpha · 19d ago
- Melanoma Trial Results Could Be A Game Changer For Iovance Biotherapeutics (IOVA) Yahoo Finance · 19d ago
- Why Did IOVA Stock Jump Over 10% After-Hours Today? TradingView · 19d ago
- Why Did IOVA Stock Jump Over 10% After-Hours Today? Yahoo Finance · 19d ago
- Iovance stock falls after lung cancer trial data disappoints Yahoo Finance · 19d ago
- Can Iovance Stock Fall 50%? Trefis · 19d ago
- Iovance sees long-term response for Amtagvi in first-line melanoma (IOVA:NASDAQ) Seeking Alpha · 19d ago
- Why is Iovance Biotherapeutics stock sliding today? Investing.com · 19d ago
- IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says ‘Selling Is Not Done’ Yahoo Finance · 19d ago
- Iovance, A Top 1% Biotech Stock, Crashes In A Surprise Lung Cancer Twist Investor's Business Daily · 19d ago
Topics
Related trends
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Brent Crashes 7% on Iran Peace Hopes Despite Fresh Saudi Pipeline Attack
Brent crude drops below $90 for the first time since August after Trump signals Iran war is 'effectively over' despite Saudi pipeline attack.
Stock futures rise slightly as investors eye AI trade, brace for more data and earnings: Live updates
Stock futures rallied as investors bought the dip following a volatile week, though Nvidia shares dropped premarket.
Bloom Energy Stock Rallies as Barclays Turns Bullish on California Power Partnership
Bloom Energy stock rallies following a strategic California power partnership and a bullish shift by Barclays.
AP Top 25 poll: Georgia reclaims No. 1 spot, Ohio State plummets in college football rankings
Georgia reclaimed the AP Top 25's No. 1 spot while Ohio State fell to No. 21, sharpening the college football rankings debate.